


Human Intelligence Enhanced by Artificial Intelligence

A REVOLUTION IN CARDIOVASCULAR IDENTIFICATION AND MANAGEMENT


CardioCare

Digital Health Platform

The CardioCare platform identifies at-risk patients with heart failure and a reduced ejection fraction (HFrEF) who could benefit from guideline-directed medical therapy (GDMT).



FEW HFrEF PATIENTS OBSERVED ON GDMT DESPITE KNOWN BENEFITS¹



¹Analysis from egnite's database of sites participating in the CardioCare platform representing 5 heart programs (both teaching and non-teaching included) managing a total of more than 50,000 patients with HFrEF. Here, GDMT includes an ACEi/ARB/ARNi, beta blocker, mineralocorticoid receptor antagonist, and SGLT2 inhibitor per the 2022 AHA/ACC/HFSA guidelines for heart failure.

DELIVERING ON DEMAND INSIGHTS OF YOUR HFREF PATIENT POPULATION TO
REDUCE VARIABILITY IN CARE & HELP ENSURE GDMT



The CardioCare platform provides insights to help you improve survival and reduce hospitalizations for your heart failure patients.



Automatically identify HFrEF patients who are not receiving full GDMT.



Guide facility- and MD-level outreach for patient evaluation and follow-up.



Ensure eligible HFrEF patients with multiple hospitalizations receive appropriate GDMT.

For more information, please visit egnitehealth.com/solutions

[@egnitehealth](https://twitter.com/egnitehealth) [in linkedin.com/company/egnite-health/](https://www.linkedin.com/company/egnite-health/)

The CardioCare platform is not intended for use in the diagnosis, cure, mitigation, or prevention of cardiovascular diseases.

©2022 egnite, Inc. All Rights Reserved. egnite, egnite Inc., the spark logo, CardioCare, and the heart logo are trademarks of egnite, Inc or its affiliates. All other trademarks are property of their respective owners.

